| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6914194e08bdf2461aff2219f5962d3e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-54 |
| filingDate |
2022-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5772eef817ac43a7bd8db68b52144bd1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_508e18bed1a1337d76440a946f398117
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f4d0eba70850853b4c8a45ba9c941ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78eadc8f21e895fad8dc5290d88a6a4d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcd98ff21d52e50b0a6fa4bca27d16f3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fbcc548b46b4803ca882413e1460b37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f49a27c6173d411ad99e53cff74409b0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b395c6fc9b9213a11e7115ca5061ecad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a14c057d2277c9d896ddfc4e3e12052d |
| publicationDate |
2023-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2023274380-A1 |
| titleOfInvention |
UNIVERSAL CAR-T CELL TARGETING IL13Rα2, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF |
| abstract |
A modified immune effector cell: the functions of T-cell antigen receptors (TCR) and major histocompatibility complexes (MHCI and MHCII) in the modified immune effector cell are inhibited in T cells, and the modified immune effector cell comprises a chimeric antigen receptor (CAR) which targets IL13Rα2. The modified immune effector cell knocks out TCR and HLA-A genes expressed by cells while recognizing tumor cell surface antigens, so as to improve the anti-tumor effect of CAR-T cells and prolong the cell survival time, while reducing the multiple effects of immunological rejection induced by allogeneic cell therapy. |
| priorityDate |
2021-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |